Clinical Trial

A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors

Study acronym: NbTAST-01
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The investigational drug, SOA101, is a nanobody-based trispecific antibody T cell engager targeting PD-L1/HLA-G/CD3. This is a Phase I/IIa study including dose-escalation, dose optimization and dose expansion parts to exam safety, tolerability, pharmacokinetics, immunogenecity and efficacy of SOA101 on advanced or metastatic solid tumor treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-07; most recent amendment 2025-11-04.
Status change: Not Yet Recruiting → Recruiting 2025-07-28
Trial Details
NCT Number NCT07055594
Lead Sponsor Shine-On Biomedical Co., Ltd.
Conditions Solid Tumors
Enrollment 76 participants
Start Date 2025-07-30
Primary Completion 2028-02 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-06